Phase 2 N=14 Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Median Overall Survival — 231 Days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=110 Efficacy of Penile Traction Therapy Using a Novel Device
Penile Diseases
Primary: Adverse Events at Baseline — 2; 2; 1; 7 percentage of participants
Phase 2 N=63 A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
Locally Advanced or Metastatic NRAS Mutant Melanoma
Primary: Number of Dose Limiting Toxicities (Phase Ib) — 2; 0; 1; 3 occurrence
Phase 3 N=200 A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -17.4; -20.1 units on a scale — p=<.001
N/A N=40 Telehealth-Based Resistance Training Intervention for Endometrial Cancer Survivors
Endometrial Cancer
Primary: Feasibility - Number of Participants Recruited — 20; 20 Participants
Phase 3 N=329 A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants Achieving Investigator's Global Assessment (IGA) of 0 or 1 With a ≥ 2 Point Improvement — 14.7; 23.9; 30.6 percentage of participants — p=0.082
N/A N=41 Computer-Based Treatment for Social Anxiety Disorder
Social Anxiety Disorder
Primary: Change in Percent Dwell Time on Threat Faces — 20.7; 27.1 percentage of dwell time on threat faces
Phase 2 N=20 Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Objective Response Rate (ORR) — 60.0 percentage of participants
Phase 3 N=695 Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy
Atrophy
Primary: Percentage of Subjects Identified as Responders — 36.8; 32.0; 0.8 percentage of responders
Phase 1 N=27 Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer
Stage IIIA Hepatocellular Carcinoma · Stage IIIB Hepatocellular Carcinoma · Stage IIIC Hepatocellular Carcinoma
Primary: Maximum Tolerated Dose (MTD) — 240 mg of nivolumab, IV
Phase 1 N=30 Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions
Bioequivalence
Primary: AUC0-tlast — 10400.038; 9907.948 ng*hr/mL — p=0.0000
Phase 1 N=34 Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz
Hyperlipidemia · HIV
Primary: AUC — 85.3; 62.8 ng*hr/mL
N/A N=18 Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT
Unexplained Infertility · Polycystic Ovarian Syndrome · Anovulatory
Primary: LH Surge — 9; 9 Participants
Phase 2 N=122 Clinical Evaluation of Metal Panel Allergens: Dose Response Study
Dermatitis, Eczematous
Primary: Number of Participants With Patch Test Responses — 0; 105; 16; 0 Participants
N/A N=216 Ostomy Telehealth For Cancer Survivors
Colostomy Stoma
Primary: Patient Activation Measure (PAM), a 100 Point Scale Determining Patient Engagement in Healthcare. — 66.9; 64.2; 67.6; 66.2 score on a scale — p=0.06